


Looking Forward: State-of-the-Art Prostate Cancer Management

SATURDAY, MARCH 25, 2023

The Whitley Atlanta Buckhead

www.Northside.com/NHCI2023symposium



PLANNING COMMITTEE

Ahmed Ali, MD
Daniel J. Canter, MD
L. Crain Garrot, MD
Vahan Kassabian, MD
William Lavelly, MD
S. Tariq Mahmood, MD
Andrew Pridjian, MD

FACULTY

Eleni Efstathiou, MD, PhD
Houston Methodist Cancer Center
Houston, TX

Felix Feng, MD
University of California, San Francisco
San Francisco, CA

Saum Ghodoussipour, MD
Rutgers Cancer Institute of New Jersey and
Rutgers Robert Wood Johnson Medical School
New Brunswick, NJ

Celestia Higano, MD
University of Washington School of Medicine
Seattle, WA

Maha Hussain, MD
Northwestern University
Chicago, IL

Amir Lebastchi, MD
Keck School of Medicine of
University of Southern California
Los Angeles, CA

Gerard Morton, MD, FABS
Odette Cancer Centre –
Sunnybrook Health Sciences Centre
Toronto, ON, Canada

Steven P. Rowe, MD, PhD
Johns Hopkins Medicine
Baltimore, MD

A. Oliver Sartor, MD
Tulane University School of Medicine
New Orleans, LA

Neal Shore, MD, FACS
GenesisCare
Carolina Urologic Research Center
Myrtle Beach, SC

Tian Zhang, MD
UT Southwestern Medical Center
Dallas, TX

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

- Identify the latest information and practice standards for cytoreductive radical prostatectomy and focal therapy for localized prostate cancer
- List practical tips for genetic testing in prostate cancer management
- Describe radiation therapy options based on disease risk categorization
- Recognize recommendations for androgen deprivation therapy throughout the prostate cancer continuum
- Explain how prostate cancer management has evolved over the last 25 years
- Summarize how PSMA-based imaging and radiopharmaceuticals are utilized for prostate cancer
- Discuss contemporary management for oligometastatic disease
- Debate the challenges in choosing initial therapy for castration-sensitive prostate cancer as well as sequencing therapies for metastatic castration-resistant prostate cancer